• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Patients size up physicians

Article

Better diagnosis, better compliance and less waste are goals of patient evaluation surveys

A pilot program has shown the feasibility of conducting scientifically valid national surveys of patients regarding their doctors and providing the reports publicly.

Consumers' Checkbook/Center for the Study of Services (CSS), a nonprofit consumer research organization, surveyed patients in Kansas City, Denver, and Memphis.

Participating plans also agreed to license the survey results for a fee to use as they see fit. (Non-participating plans will not be granted use of the survey results.) According to the company, the survey model costs about $100 to $120 per doctor.

Aetna's Chief Medical Officer Lonny Reisman, MD, believes the approach improves the health plan's ability to gather sufficient patient feedback on each doctor to provide scientifically valid and meaningful information.

"The more people weighing in, the more credible and useful the information will be," Dr. Reisman says. "Sharing reliable patient input with doctors and consumers adds a valuable dimension to existing tools that engage health plan members by helping them evaluate quality as well as cost."

Physicians in the pilot metro areas have been cooperative in survey efforts, says Krughoff.

Related Videos
Video 2 - "Traditional Treatment of Demodex Blepharitis, FDA approval, and Lotilaner Ophthalmic Solution, 0.25%"
Gabriela Hobbs, MD, an expert on polycythemia vera
Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Video 8 - "Risk and Value-Based Contracting for Prescription Drug Therapeutics and Manufacturer’s Support in Utilization"
Video 7 - "Prescribing Prescription Drug Therapeutics: Factors for Providers and Payers to Consider"
© 2024 MJH Life Sciences

All rights reserved.